About Qiagen
Qiagen is a provider of sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research.
Leadership Team
Leadership as listed on qiagen.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.
Products & Services
Products and services as listed on qiagen.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.
QIAstat-Dx
Syndromic molecular testing platform, including a viral vesicular panel for mpox surveillance.
Source: qiagen.comQIAcuity dPCR System
Digital PCR system for research use; QIAcuityDx is the automated version for IVD applications.
Source: qiagen.comQIAsymphony Connect
Next-generation automated IVD nucleic acid extraction platform built on the QIAsymphony SP.
Source: qiagen.comQuantiFERON-TB Gold Plus
QuantiFERON test featured on the QIAGEN site; a QuantiFERON Transplant product is also listed.
Source: qiagen.comQIAseq
Library and targeted panel kits for next-generation sequencing, including RNA-seq and viral/bacterial panels.
Source: qiagen.comtherascreen
Oncology testing line; therascreen Solid Tumor is featured on the site.
Source: qiagen.comBioinformatics
Digital tools helping research and clinical labs design experiments and analyse genomic data.
Source: qiagen.comPipeline & Regulatory Record
What public registers list for Qiagen: clinical trials it sponsors, FDA device clearances, Irish licences, recent approvals and supply shortages. Rebuilt daily, last on 3 Oct 2026.
Clinical trials 3 in our ClinicalTrials.gov registers
| Study | Phase | Status |
|---|---|---|
| Clinical Performance Evaluation of the QIAstat-Dx® cUTI Plus AMR NCT06824129 · Complicated Urinary Tract Infection |
Observational | Active, closed |
| Clinical Performance of QIAstat-Dx® Meningitis/Encephalitis (ME) Panel Plus NCT06820060 · Meningitis, Encephalitis Infection |
Observational | Active, closed |
| DHF-20-1839-2: Clinical Performance Study Protocol for Therascreen® KRAS RGQ PCR Kit NCT06645236 · Metastatic Colorectal Cancer (mCRC) |
Not applicable | Recruiting |
All trials by sponsor name 1 registry name
FDA 510(k) device clearances 1
- QIAstat-Dx BCID GPF Plus AMR PanelK254194 · QIAGEN GmbH · 6 Aug 2026 · Class 2
Clearances in our FDA device register: every clearance to an Irish-based applicant, plus the last 90 days worldwide.
Group (Qiagen): founded 1984, headquarters Venlo, website qiagen.com. Wikidata Q315287 · Wikipedia. From Wikidata (CC0), matched by the group's SEC filer number.
How this is matched: register records are linked to this page by the organisation name they carry, here QIAGEN Gaithersburg, Inc; QIAGEN GmbH. Spot a wrong match? Tell us.
Financials & Irish Entities
From the annual reports QIAGEN N.V. files with the US Securities and Exchange Commission (20-F, US GAAP), in USD as reported. Latest financial year: to Dec 2025.
| Year to | Revenue | R&D | R&D % | Net income | Filing |
|---|---|---|---|---|---|
| Dec 2025 | $2.09bn | $188m | 9.0% | $425m | 20-F 2026 |
| Dec 2024 | $1.98bn | $193m | 9.8% | $83.6m | 20-F 2026 |
| Dec 2023 | $1.97bn | $199m | 10.1% | $341m | 20-F 2026 |
| Dec 2022 | $2.14bn | $190m | 8.9% | $423m | 20-F 2025 |
| Dec 2021 | $2.25bn | $190m | 8.4% | $513m | 20-F 2024 |
R&D is shown as tagged in the filing, which for this company can exclude acquired in-process R&D. Each year is taken from the most recent annual report that includes it, so earlier years reflect any later restatement. Source: SEC EDGAR (XBRL financial data). Compare companies on the pharma company financials register.